Device Trial Radar · NCT04506866
InterStim Micro Post Market Clinical Follow-up Study (ELITE)
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
148
Actual
Start
Aug 25, 2020
Primary completion
Dec 19, 2022
Study completion Dec 8, 2023
Sponsor
- Lead sponsor
- MedtronicNeuroNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 10, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.
Conditions
- Overactive Bladder
- Fecal Incontinence
- Non-obstructive Urinary Retention
Interventions
InterStim MicroDevice
Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline for HRQL Total ScoreTime frame: 3 months
- Change From Baseline in CCIS ScoreTime frame: 3 months
- Change From Baseline in the Number of CISC/DayTime frame: 3 months
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
East Coast Institute for Research
Jacksonville, Florida
Florida Urology Partners
Tampa, Florida
First Urology
Jeffersonville, Indiana
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.